AADAT

Across TCGA pan-cancer cohorts, AADAT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AADAT data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AADAT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AADAT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where AADAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.785	0.123	.009	27	view →
LSCC	OS	Median	II,III,IV	0.943	0.474	.003	22	view →
GBM	DFS	Median	All	0.808	0.620	.001	14	view →
LUAD	DFS	Median	II,III,IV	1.000	0.615	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AADAT–CCRCC (OS)

Open the CCRCC breakdown →